Testosterone manufacturers and suppliers

Testosterone suppliers

Properties

Melting point:: 152-156 °C

alpha: 101 º (c=1, dioxane 25 ºC)

Boiling point:: 370.65°C (rough estimate)

Density: 1.0484 (rough estimate)

refractive index: 1.4709 (estimate)

Flash point:: 5 °C

storage temp.: 2-8°C

solubility: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: soluble18.2 mg/ml

pka: 15.06±0.60(Predicted)

form: powder

optical activity: [α]20/D +110±2°, c =1% in ethanol

Water Solubility: 22.79mg/L(20 ºC)

Merck: 13,9255

BRN: 1915399

Henry's Law Constant: 2.8×10³ mol/(m³Pa) at 25℃, HSDB (2015)

Stability:: Stable. Combustible. Incompatible with strong oxidizing agents.

Cosmetics Ingredients Functions: SKIN CONDITIONING

InChI: 1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1

InChIKey: MUMGGOZAMZWBJJ-DYKIIFRCSA-N

SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O

CAS DataBase Reference: 58-22-0(CAS DataBase Reference)

NIST Chemistry Reference: Testosterone(58-22-0)

EPA Substance Registry System: Testosterone (58-22-0)

Safety Information

Symbol(GHS): GHS07,GHS08,GHS09

Signal word: Danger

Hazard statements: H302-H351-H360FD-H400

Precautionary statements: P202-P264-P270-P273-P301+P312-P308+P313

PPE: Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Hazard Codes: T,Xn,F

Risk Statements: 60-61-11-19-20-40-63-45-36-20/21/22-38

Safety Statements: 53-45-24/25-36/37-26-16

RIDADR: UN 2252 3/PG 2

WGK Germany: 3

RTECS: XA3030000

TSCA: TSCA listed

HS Code: 29372900

Storage Class: 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects

Hazard Classifications: Acute Tox. 4 Oral
Aquatic Acute 1
Carc. 2
Repr. 1B

Hazardous Substances Data: 58-22-0(Hazardous Substances Data)

Toxicity: LD50 oral in mammal (species unspecified): > 5gm/kg

REACH Registrations: Active

Use

In Osteoporosis: Testosterone replacement is not FDA approved for the prevention or treatment of osteoporosis. It should not be used solely for these indications but might be beneficial to reduce bone loss in patients needing therapy for hypogonadal symptoms. In a few studies, women receiving oral methyltestosterone 1.25 or 2.5 mg daily or testosterone implants 50 mg every 3 months had increased BMD. Various salt forms of testosterone were associated with increased BMD in some studies of hypogonadal men or senior men with normal hormone levels or mild hormonal deficiency. Transdermal gel, oral, intramuscular, and pellet testosterone products are available. Patients using them should be evaluated within 1 to 2 months of initiation and then every 3 to 6 months thereafter.

You can find Testosterone suppliers, manufacturers, and distributors from countries such as China, India and the United States here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.